AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer

AstraZeneca Plc’s AZN top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer.
The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed early enough for the tumor to be surgically removed and have a mutation of the EGFR gene.
The approval was based on positive results from a late-stage trial, ADAURA, which showed Tagrisso cut the risk of the tumor growing back in patients or death by 80%.
Tagrisso brought in sales of $1.15 billion in the first quarter.
Price Action: AZN shares are down 0.21% at $56.77 in the premarket session on the last check Friday.